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Abstract
Insulin from the β-cells of the pancreatic islets of Langerhans controls energy homeostasis in 
vertebrates, and its deficiency causes diabetes mellitus. During embryonic development, the 
transcription factor Neurogenin3 initiates the differentiation of the β-cells and other islet cell types 
from pancreatic endoderm, but the genetic program that subsequently completes this 
differentiation remains incompletely understood. Here we show that the transcription factor Rfx6 
directs islet cell differentiation downstream of Neurogenin3. Mice lacking Rfx6 failed to generate 
any of the normal islet cell types except for pancreatic-polypeptide-producing cells. In human 
infants with a similar autosomal recessive syndrome of neonatal diabetes, genetic mapping and 
subsequent sequencing identified mutations in the human RFX6 gene. These studies demonstrate a 
unique position for Rfx6 in the hierarchy of factors that coordinate pancreatic islet development in 
both mice and humans. Rfx6 could prove useful in efforts to generate β-cells for patients with 
diabetes.
During embryonic development, the pancreas first appears as clusters of cells on the dorsal 
and ventral aspects of the gut endoderm. The exocrine and endocrine cells that form the 
adult pancreas differentiate from this pool of pancreatic progenitors 1. A single transcription 
factor, the pro-endocrine bHLH factor Neurogenin3, is both necessary and sufficient to drive 
these progenitor cells to differentiate into the endocrine cells that form the islets of 
Langerhans 2,3,4. Transient activation of Neurogenin3 expression in scattered progenitor 
cells initiates expression of additional transcription factors, including NeuroD1, Pax4, 
Nkx2.2, Nkx6.1, Arx, and others, which then direct the differentiation of those cells into the 
distinct islet cell subtypes and the activation of the mature islet transcription factors such as 
MafA, Pax6 and Isl1 1. Mutations in many of these genes can cause diabetes, highlighting 
the pathway’s importance in human beta-cell formation and insulin production5. 
Understanding and controlling this process of differentiation may ultimately provide us with 
the cells needed to treat diabetes mellitus.
Expression of Rfx6
In independent screens for genes co-expressed with Neurogenin3 in islet progenitor cells 6, 
activated by Neurogenin3 7, and uniquely expressed in islets (M.E.W. and J.D.J., 
unpublished data), we identified Rfx6, a member of the RFX (Regulatory Factor X-box 
binding) family of winged-helix transcription factors 8,9. Rfx6 transcripts could be detected 
in mouse and human embryonic pancreas by RT-PCR (Fig. 1a,b), but, unlike all other 
known islet transcription factors, not in brain (Fig. 1a, c), and not in mouse embryonic 
pancreas lacking Neurogenin3 (Fig. 1d). In contrast, mouse Rfx4, the mammalian RFX gene 
with the highest homology to Rfx6, was amplified from brain and not from pancreas, and the 
other RFX genes were more widely expressed (Fig.1a).
To explore the pattern of Rfx6 protein expression, we used antiserum generated against 
recombinant Rfx6 protein for immunofluorescence studies. In mice, Rfx6 was detected as 
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early as embryonic day 7.5 (e7.5) throughout the definitive, but not extraembryonic, 
endoderm and persisted broadly in gut endoderm at e9.0, after which it becomes 
progressively restricted to the pancreas and scattered cells in the gut (Fig. 2a-c, 
Supplemental Fig. S1 and data not shown). At e10.0, immunofluorescence staining detected 
Rfx6 in foregut/midgut epithelium and in scattered cells in the nascent pancreatic buds, as 
indicated by staining for pancreatic transcription factor Pdx1 (Fig. 2d-f). Most of these 
scattered Rfx6-expressing cells did not co-express Pdx1, but many co-expressed Nkx2.2 and 
Neurogenin3 (Supplemental Figs. S1 and S2). By e12.5, the Rfx6-expressing cells were 
generally distinct from the Pdx1-expressing progenitor cells, but most co-expressed 
glucagon, demonstrating restricted expression of Rfx6 in the endocrine lineage even at this 
early stage (Supplemental Fig. S3). In pancreata from Neurog3-/- embryos 10, there were no 
Rfx6-expressing cells (Supplemental Fig. S4).
During the peak of endocrine cell differentiation at e15.5, Rfx6 co-localized with 
Neurogenin3 in the nuclei of a subset of the endocrine progenitor cells (Fig 2g), and 
overlapped with the islet transcription factors Nkx2.2, Nkx6.1, and Pdx1 (Supplemental Fig. 
S5). At e18.5, Rfx6 could be found in the nuclei of cells expressing each of the major 
pancreatic endocrine hormones (Fig. 2h and Supplemental Fig. S6). In the adult pancreas, 
Rfx6 expression was restricted to the islets where it could be detected in all endocrine 
lineages (Fig.2i and Supplemental Fig. S7).
To generate Rfx6 null mice, we used homologous recombination to replace the first five 
exons of the Rfx6 gene, including the sequences encoding the DNA-binding domain, with a 
cassette encoding an eGFP-cre fusion protein (Supplementary Fig. S8). By crossing mice 
heterozygous for the mutant allele with mice carrying the marker gene ROSA26 loxP-stop-
loxP lacZ (R26R) 11, we generated Rfx6+/eGFPcre/R26R double heterozygous mice in which 
Rfx6-expressing cells and their descendents are marked by the expression of β-galactosidase 
and can be visualized with the X-gal substrate (Fig. 3a-d and Supplemental Fig. S9). β-
galactosidase expression was detected in all embryonic tissue derived from the endoderm 
germ layer, but not in other embryonic or in extraembryonic tissues, demonstrating that 
Rfx6 is broadly expressed in and restricted to the definitive endoderm prior to the formation 
of the endoderm-derived organs. Taken together, the immunohistochemistry data and 
lineage tracing demonstrate that Rfx6 is expressed initially broadly in the definitive 
endoderm after gastrulation, becomes restricted to the gut and pancreatic bud at mid 
gestation, is reactivated by Neurogenin3 in islet progenitor cells and is ultimately restricted 
to pancreatic islets in the mature pancreas.
Rfx6eGFPcre/eGFPcre mice
From heterozygous crosses, homozygous Rfx6eGFPcre/eGFPcre mice were born at the 
expected Mendelian ratio, but failed to feed normally, exhibited gross bowel distension due 
to small bowel obstruction (Fig. 3e-f) and died within 2 days post partum. Some, but not all, 
of the Rfx6 null animals also had reduced pancreas size (data not shown).
To test for effects on gene expression prior to birth, we harvested RNA from e17.5 
pancreata, and used low density TaqMan arrays 6 to measure the levels of a set of pancreatic 
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genes (Supplemental Table S1). Rfx6 eGFPcre/GFPcre pancreata had almost no expression of 
the islet hormones genes, except for pancreatic polypeptide (Ppy). Several other islet/β-cell 
genes, such as the zinc transporter Slc30a8 and G-protein coupled receptor GPR40/Ffar 
genes, were similarly reduced; but other β-cell genes were more modestly reduced, including 
the glucose sensing genes Gck, Slc2a2, and Kcnj11. Immunofluorescence staining with the 
endocrine markers Chromogranin A or Synaptophysin at e17.5 demonstrated that the 
Rfx6 eGFPcre/eGFPcre pancreata still contained a large number of endocrine cells, but 
confirmed that none of these cells expressed insulin, glucagon, somatostatin or ghrelin (Fig. 
4). Although the number of Ppy-expressing cells was increased in the Rfx6 eGFPcre/eGFPcre 
pancreata, they only accounted for a subset of the endocrine cells (Fig. 4i-l), leaving the 
identity of the remaining endocrine cells unknown.
We also tested whether Rfx6 regulates other transcription factor genes (Supplemental Table 
S2). The absence of Rfx6 did not affect Neurogenin3 expression, and this was confirmed at 
the protein level (data not shown). In sharp contrast, expression of genes downstream of 
Neurogenin3 encoding factors involved in alpha-cell development, including Irx2 and Arx, 
was markedly reduced in Rfx6 eGFPcre/eGFPcre pancreata.
Interestingly, genes encoding several factors involved in insulin gene transcription (Pax6, 
MafA, NeuroD1 and Pdx1) also had reduced expression, but some key genes involved in β-
cell specification either did not significantly change (Nkx2.2 and Nkx6.1), or increased 
(Pax4). Immunofluorescence staining at e17.5 revealed that the field of Nkx6.1 expression 
expanded from β-cells alone in wildtype pancreata to include all of the Chromogranin A + 
endocrine cells, including the PP cells in Rfx6 eGFPcre/eGFPcre pancreata (Fig. 4i-l and 
Supplementary Table S3). These studies suggest that while Rfx6 regulates the transcription 
factors involved in β-cell maturation and function, it restricts the expression of the β-cell 
differentiation and specification genes, and thus the β-cell fate choice.
Mice with a targeted disruption of the Rfx3 gene have an islet phenotype that is similar to, 
but less extreme than, the Rfx6 eGFPcre/eGFPcre mice, with reductions in the numbers, but not 
complete loss, of insulin- and glucagon-expressing cells and an increase in pancreatic 
polypeptide-expressing cells 12. In a proteome-wide screen of protein-protein interactions, 
Rfx6 was found to interact with Rfx2 and 3 13. Since the RFX transcription factors generally 
bind to their target DNA sites (the “X box”) as dimers 14, we tested whether Rfx6 and Rfx3 
form a heterodimeric DNA binding complex in an electromobility shift assay (EMSA). We 
found that both full length Rfx3, and truncations that retain the DNA-binding and 
dimerization domains, bound to an X box site together with Rfx6 (Fig. 5a and 
Supplemenatry Fig. S10), and that the two factors cooperated in activating a promoter 
containing multimers of this X box site (Fig 5b).
It has been proposed that the islet phenotype of the Rfx3-/- mice results from defects in 
primary cilia formation on islet cells 12, although islets lacking any primary cilia develop 
fairly normally 15,16. Unlike in the Rfx3-/- mice, we found that primary cilia formation was 
unaffected in the Rfx6 eGFPcre/eGFPcre islets (Supplementary Fig. 11a-d). In addition, 
expression of the cilia genes Ift88 and Dync2li1, which are reduced in the pancreas of Rfx3-/- 
mice12, was not reduced in the pancreas of Rfx6 eGFPcre/eGFPcre mice (Supplementary Fig. 
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11e). We conclude that Rfx3 and Rfx6 cooperate in regulating a set of genes involved in 
islet development but not in cilia formation. The more modest islet phenotype in the Rfx3-/- 
mice may be due to the ability of Rfx2 to compensate partially for the loss of Rfx3 (Fig. 1a), 
or the ability of Rfx6 to direct gene expression as a homodimer (Fig. 5a, b).
Human mutations in RFX6
The phenotype of the Rfx6 eGFPcre/eGFPcre mice is remarkably similar to human patients 
born with neonatal diabetes and small bowel obstruction due to bowel atresia17, 18. Despite 
some reduction in pancreatic size, these cases were not deficient in enzymes of the exocrine 
pancreas, and autopsies of two cases (proband #1 and case 3 in Ref 17) revealed normal-
appearing exocrine pancreata with clusters of ChromograninA-positive cells but total 
absence of cells staining for insulin, glucagon, or somatostatin17. In addition, the syndrome 
involves hypoplastic gall bladder, and intractable diarrhea unresponsive to pancreatic 
enzyme replacement.
The disease locus was mapped using overlapping homozygosity in probands #1and #2 (see 
Supplementary material for pedigree information and references to previous clinical case 
reports) respectively the offspring of first and second cousins. High-resolution 
homozygosity mapping identified 10 homozygosity-by-descent (HBD) segments >500 kb in 
proband #1 (after excluding those that overlapped with her unaffected sibling, 
Supplementary Table S4), and 25 HBD segments >500kb in proband #2 (Supplementary 
Table S5). Only three HBD regions were common in the two probands, totaling 24 Mb 
(Table 1). Altogether, 194 RefSeq genes map to these regions. Of these genes, only RFX6, 
which falls in the largest segment at 6q21-22, had pancreas–enriched expression in the 
TiGER database 19 (Supplementary Table 6), and also increased in expression in human 
pancreas between foetal ages 10 and 20 weeks (Fig. 1b and Supplementary Figs. S13 and 
S14), concordant with the appearance of endocrine cells 20,21.
Two parallel, independent approaches unequivocally identified mutations in the RFX6 gene 
in this human syndrome: direct sequencing of the RFX6 gene and unbiased deep sequencing 
of all exons within the three overlapping HBD regions.
For deep sequencing, exons were captured from DNA obtained from Proband #2 using a 
tiled oligonucleotide array22 covering 1,309 of 1,322 exons mapping within the HBD 
regions23. Amplification and sequencing24 of the captured fragments generated 40,379 
sequences of at least 100 bp that aligned within the target regions. Median target coverage 
depth was 9.2, with 80% of targets having a depth of at least 4. Given that we were 
searching for a homozygous mutation, this was sufficient for unequivocal detection of 
exonic variants. Altogether, 30 novel sequence variants were detected (Supplementary Table 
S7): 15 in introns, 3 in both introns and untranslated regions (UTRs), 9 in UTRs, and only 
three in coding sequences, two synonymous. The only non-synonymous variant was 217 
Ser>Pro in RFX6, identifying this gene as the most likely candidate.
In parallel, direct sequencing was performed on the 19 exons and the splicing junctions of 
RFX6 in all probands. Missense, splicing or frameshift mutations in RFX6 were found in 
five of the six available probands (Fig. 5e) with an interesting genotype-phenotype 
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correlation. Probands #1, 4 and 5 all died in the first few months of life and were 
homozygous for, respectively, a loss of the donor splicing site in intron 2 (IVS2+2 t>c), an 
out-of-frame deletion in exon 7, and the missense mutation 181 R>Q involving a highly 
conserved arginine in the DNA-binding domain 8,25(Supplementary Fig. S15). Proband #3, 
still alive at the age of 9 and intermittently off insulin, was a compound heterozygote for 
donor-site loss in intron 6 (IVS6+2 t>g) and disruption of the acceptor site in intron 1 
(IVS1-12 a>g). Proband #2, still alive at age 4.5 years18, had the homozygous missense 
mutation 217 Ser>Pro, confirming the unbiased exon sequencing described above. All 
mutations were inherited from carrier parents.
To determine the significance of the homozygous intron 2 splice donor splicing site 
mutation in proband #1, we amplified RFX6 mRNA by RT-PCR of high-quality RNA from 
autopsy pancreas and failed to detect the properly spliced transcript, which was easily 
amplified from normal foetal pancreas as was the reference gene cyclophilin in the 
proband’s RNA. We also failed to detect any RNA from exons 1+2, upstream of the splicing 
mutation, probably due to nonsense-mediated decay26(Supplementary Fig. S16).
We also tested the two missense mutations for their effect on DNA binding by Rfx6. We 
found that 181R>Q (proband #5), which alters a conserved amino acid in the DNA binding 
domain, completely abrogated DNA binding, while 217S>P (proband #2), which lies 
between the DNA-binding domain and dimerization domain of Rfx6, only modestly reduced 
DNA binding (Fig. 5d) and did not affect dimer formation (data not shown).
Finally, we failed to identify any mutation in RFX6 in proband #6. In the absence of DNA 
from the proband, we sequenced both parents and found no point mutation of RFX6 or 
NEUROG3; and long-range PCR did not reveal any deletions of RFX6 (Supplementary Fig. 
S17). In the absence of proband DNA we cannot rule out a de novo mutation, but this case is 
most likely a phenocopy. We also failed to find RFX6 mutations in a case of the Martinez-
Frias syndrome27. Finally, a search of the RFX6 linkage disequilibrium block in our 
genome-wide association data 28,29, combined with those of the WTCC 30, did not reveal 
any common variants associated with type 1 or type 2 diabetes (data not shown).
Discussion
In the pancreas, Rfx6 acts downstream of the pro-endocrine factor Neurogenin3 (Fig. 5c), 
and mutation of the two genes give similar but distinct phenotypes. Like RFX6 mutations, 
mutation of NEUROG3 in humans also causes intractable diarrhoea and diabetes 31, but 
NEUROG3 mutation does not cause the small bowel atresia or biliary abnormalities seen 
with RFX6 mutation, which is not surprising since Neurogenin3 is not expressed in the early 
gut endoderm as is Rfx6 4,32,33. Despite severe intestinal malabsorption, pancreatic exocrine 
function is intact in both syndromes, and the only histological abnormality in the gut in the 
mutant NEUROG3 syndrome is loss of the intestinal endocrine cells 34. Comparison of the 
gut endocrine cells affected by these two related syndromes may provide new insight into 
mechanisms that regulate nutrient absorption in the small bowel.
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In addition, RFX6 mutations cause diabetes at birth, while the reported patients with 
homozygous mutations in Neurogenin3 did not develop diabetes until several years later 31, 
despite evidence that Neurogenin3 is absolutely required for the generation of islet cells and 
production of insulin in mice 2. Incomplete loss of function in the reported human 
NEUROG3 mutations could explain the continued insulin production in these patients 35. 
Alternatively, recent evidence that Neurog3-/- mice still generate a small number of islet 
cells 36 suggests some redundancy of Neurogenin3’s pro-endocrine function, possibly due to 
the presence of related bHLH proteins in the pancreas 4,7. In contrast, our data do not 
indicate any redundancy of Rfx6 function in endocrine differentiation and demonstrate 
remarkable conservation of the genetic control of islet development, despite some 
discrepancy between mouse and human NEUROG3 mutants.
It should be noted that our patients with RFX6 mutations have some similarities with other 
reported cases, especially those with the Martinez-Frias syndrome (MFS)27, under which 
OMIM currently lists our cases. However, since the original MFS patients also had 
oesophageal atresia and hypospadias, and did not have diabetes, and we did not find any 
RFX6 mutation in the parents of one case of MFS, our cases are distinct from MFS. We 
propose to name their condition, now of defined molecular aetiology, the Mitchell-Riley 
syndrome after the two clinicians who first described it17.
In summary, we have identified a novel factor in endoderm and islet development, Rfx6, 
that is required for the differentiation of 4 of the 5 islet cell types and for the production of 
insulin in both humans and mice. In the hierarchy of islet developmental factors, it lies 
downstream of Neurogenin3 and upstream of many of the other islet transcription factors 
(Fig. 4d). A full understanding of the role of Rfx6 will help to clarify how islets and β-cells 
are generated, what goes wrong in this process in diabetes, and how to generate new β-cells 
for patients with diabetes.
Methods summary
All studies involving mice were approved by the UCSF Institutional Animal Care and Use 
Committee. Timed matings were carried out with embryonic day 0.5 being set as midday of 
the day of discovery of a vaginal plug. The Rfx6 targeting allele (Supplementary Fig. S8) 
was generated by recombineering in a modified bacterial artificial chromosome followed by 
recombination into plasmid DNA by gap-repair 38. This construct was used by the UCSF 
DERC Transgenic Core Laboratory to target the Rfx6 allele in 129 (E14) mouse embryonic 
stem cells, which were injected into mouse blastocysts to generate chimeric Rfx6 +/eGFPcre 
mice. Chimeras and subsequent generations were crossed to C57BL/6 mice. Mouse tissue 
processing, β-galactosidase detection, immunofluorescence staining 39, automated cell 
counting 40, transfections of mPAC cells, EMSA 41 and mRNA quantification with low 
density TaqMan arrays 6 were performed as previously described. All antisera used for 
immunofluorescence studies are listed in Supplementary Table S8. Sequences of 
oligonucleotides used for RT-PCR, ESC colony screening, mouse genotyping and EMSA 
are available on request.
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The human subjects protocol was approved by the IRB of the Montreal Children’s Hospital 
and written informed consent was obtained from all participating families. Clinical findings 
and case-report references are summarized in the web supplement. For homozygosity 
mapping, results from the Illumina Hap 550 (proband #1, call rate 0.99) or 1M (proband #2, 
call rate 0.978) microarrays37, were used to scan autosomes in 300-kb windows and HBD 
was defined as absence of any heterozygous SNP in the proband and presence of at least one 
in either parent or the unaffected sibling. Long-oligo Nimblegen capture arrays22 included 
around 100 bp extension of intronic sequence coverage from the boundary of the exons. The 
eluted enriched regions from proband #1 were run on the Roche 454 FLX Genome 
Sequencer24. The 19 exons of RFX6 were PCR-amplified manually for Sanger sequencing 
in the remaining probands. For the long range PCR, we used the Kit # K0182 from 
Fermentas for fragments ranging from 6 to 17 Kb (Supplementary Fig S17).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Expression of Rfx6 in mice and human tissues
In a, the mRNA for Rfx genes 1-6 were amplified by RT-PCR from RNA isolated from the 
pancreas and brain of mouse embryos at e17.5 and from NIH3T3 fibroblasts. In b, levels of 
RFX6 mRNA were determined by real-time PCR of RNA from whole pancreas of human 
foetuses at the ages shown. n= 5 samples per foetal age group. *p= 0.017, weeks 8-10 vs. 
19-21, by two-tailed Student’s t test. In c, mRNA for RFX6 and control gene Cyclophilin A 
(PPIA) genes were amplified by RT-PCR from RNA isolated from the human adult tissues 
shown. In d, levels of Rfx3 and Rfx6 mRNA were determined by real-time RT-PCR 
(TaqMan) of RNA isolated from the pancreata of wildtype and Neurog3-/- mouse embryos at 
e17.5 values and expressed relative to the level of Gusb. n= 3 samples per group. **p = 
0.0025, wildtype vs. mutant, by two-tailed Student’s t test.
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Figure 2. Expression of Rfx6 in mice
Immunofluorescence staining was performed for Rfx6 (red) in mouse embryos. In a - c, at 
e9, Rfx6 staining overlaps with Foxa2 in the gut epithelium (including foregut, FG) and 
nascent dorsal pancreatic bud (DP), but Foxa2 is expressed alone in the liver bud (Li) and 
extraembryonic endoderm (EE). Separate colour channels are shown for red (a and d) and 
green (b and e). In d - f, costaining was performed with Pdx1 (green) in gut (duodenum, 
Du), dorsal pancreas (DP) and ventral pancreas (VP) at e10. In g, e15.5 pancreas was 
costained for Neurogenin3 (green). Costaining nuclei appear yellow. In h, e18.5 pancreas 
was costained for insulin (green). In i, adult pancreas was costained for insulin (green). 
Higher resolution photomicrographs from additional dates with additional markers can be 
found in Supplementary Figs. 1-7. Scale bars, 25 μm.
Smith et al. Page 12
Nature. Author manuscript; available in PMC 2010 August 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Targeting of the Rfx6 gene in mice
In panel a-d, lineage tracing was performed on Rfx6 +/+/R26R (left in a and c) or 
Rfx6 +/eGFPcre/R26R (b and d, and right in a and c) mice at e10.5 (a, b) and e12.5 (c, d) by 
staining for β-galactosidase activity with Xgal (blue). Panel b shows a close-up view of the 
animal on the right in panel a, and panel d shows a close-up view of the animal on the right 
in panel c. In panel e, an Rfx6eGFPcre/eGFPcre pup at p2 is shown on the right, with a 
wildtype liter mate on the left. In panel f, the dissected abdominal viscera are shown for 
wildtype (left) and Rfx6eGFPcre/eGFPcre (right) pups at p0.5. Additional photographs of the 
lineage tracing and mutant animals can be found in Supplementary Fig. 10. Li, liver; Du, 
duodenum; GB, gall bladder; VD, vitelline duct; Th, thymus; Tr, trachea; Oe, oesophagus; 
Lu, lung; St, stomach; DP, dorsal pancreas; VP, ventral pancreas; Hg, hindgut.
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Figure 4. Expression patterns of islet markers in wildtype and Rfx6eGFPcre/eGFPcre mice at e17.5
On pancreas sections from e17.5 embryos with the genotypes shown at the left, 
immunofluorescence costaining was performed for ChromograninA (ChromoA, red, a - f, 
green k, l), Synaptophysin (Syn, red, g, h), insulin (green, a, b), glucagon (green, c, d), 
somatostatin (Sst, green, e, f), ghrelin (green g, h), Nkx6.1 (red in i - l), and pancreatic 
polypeptide (Ppy, green, k, l). Quantification of cells expressing Ppy and Nkx6.1 is shown in 
Supplementary Table S3. Scale bars, 25 μm.
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Figure 5. Function of the human Rfx6 protein
In a and c, DNA binding of the human in vitro-translated proteins shown above each lane to 
the double-stranded, radiolabeled oligonucleotide HBV X-box probe 42 was tested by 
electromobility shift assay (EMSA). In a, combined proteins were co-translated, and probe 
bound by the heterodimer partners has a mobility between that of the two homodimers. 
Truncated proteins Rfx3T1 and Rfx3T2 have the first 119 and 160 amino-terminal amino 
acids removed respectively, but retain the DNA-binding and dimerization domains. In vitro-
translated luciferase is included as a negative control. A close-up view of a longer gel is 
shown in Supplementary Fig. S10a. In b, mouse pancreatic ductal mPac L20 cells were co-
transfected with a DNA plasmid containing the reporter constructs shown and another 
expressing the RFX cDNAs shown, luciferase reporter expression was assayed for each 
combination. *p = 0.0026 vs. “no cDNA”, 0.0024 vs. Rfx3 alone, and 0.011 vs. Rfx6 alone 
by two-tailed Student’s t test. In c, a schematic shows the proposed interactions, either direct 
or indirect, of several transcription factors during pancreas development. In d, increasing 
amounts of the in vitro-translated human Rfx6 wild type and R181Q and S217P mutant 
proteins were assayed for binding to the X-box DNA probe. Efficiency of mutant protein 
production is demonstrated in Supplementary Fig. S10b. In e, mutations found in patients 
are indicated on a map of the RFX6 gene. All mutations were homozygous except for 
proband 3.
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